Evidence map›Paper›PMID 37996944›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

Transcriptomic landscape based on annotated clinical features reveals PLPP2 involvement in lipid raft-mediated proliferation signature of early-stage lung adenocarcinoma.

Yibei Wang, Ziwei Miao, Xiaoxue Qin, Yi Yang, Si Wu, Qi Miao, Beibei Li, Mingyu Zhang, Pengfei Wu, Yun Han and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yibei WangDepartment of Developmental Cell Biology, Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, Liaoning, 110122, P. R. China.
Ziwei MiaoDepartment of Developmental Cell Biology, Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, Liaoning, 110122, P. R. China.
Xiaoxue QinDepartment of Developmental Cell Biology, Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, Liaoning, 110122, P. R. China.
Yi YangDepartment of Laboratory Animals, China Medical University, Shenyang, China.
Si WuDepartment of Biobank, Shengjing Hospital of China Medical University, Shenyang, China.
Qi MiaoDepartment of Radiology, The First Hospital of China Medical University, Shenyang, China.
Beibei LiDepartment of Radiology, Shengjing Hospital of China Medical University, Shenyang, China.
Mingyu ZhangDepartment of Developmental Cell Biology, Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, Liaoning, 110122, P. R. China.
Pengfei WuDepartment of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P. R. China. wupfcmu@126.com.
Yun HanDepartment of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, P. R. China. hany@sj-hospital.org.
Bo LiDepartment of Developmental Cell Biology, Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, Liaoning, 110122, P. R. China. bli28@cmu.edu.cn.
China Medical University · CNFirst Hospital of China Medical University · CN

Funding

National Natural Science Foundation of China No. 82073242National Natural Science Foundation of China No. 82103421Science and Technology Foundation of Liaoning Province No. 1655187410844Science and Technology Foundation of Liaoning Province NO.2021JH2/10300088Shengjing Hospital of China Medical University 345 Talent Project NO.30B
6 · The paper itself

Abstract

backgroundImage-based screening improves the detection of early-stage lung adenocarcinoma (LUAD)but also highlights the issue of high false-positive diagnoses, which puts patients at a risk of unnecessary over-treatment. Therefore, more precise discrimination criteria are required to ensure that patients with early-stage LUAD receive appropriate treatments.

methodsWe integrated 158 early-stage LUAD cases from 2 independent cohorts, including 30 matched resected specimens with complete radiological and pathological information, and 128 retrospective pathological pair-samples with partial follow-up data. This integration allowed us to conduct a correlation analysis between clinical phenotype and transcriptome landscape. Immunohistochemistry was performed using tissue microarrays to examine the expression of phospholipid phosphatase 2 (PLPP2) and lipid-raft markers. Lipidomics analysis was used to determine the changes of lipid components in PLPP2-overexpressed cells. To assess the effects of PLPP2 on the malignant phenotypes of LUAD cells, we conducted mice tumor-bearing experiments and in vitro cellular experiments by knocking down PLPP2 and inhibiting lipid raft synthesis with MβCD, respectively.

resultsBioinformatics analysis indicated that the co-occurrence of lipid raft formation and rapid cell proliferation might exhibit synergistic effects in driving oncogenesis from lung preneoplasia to adenocarcinoma. The enhanced activation of the cell cycle promoted the transition from non-invasive to invasive status in early-stage LUAD, which was related to an increase in lipid rafts within LUAD cells. PLPP2 participated in lipid raft formation by altering the component contents of lipid rafts, such as esters, sphingomyelin, and sphingosine. Furthermore, elevated PLPP2 levels were identified as an independent prognostic risk factor for LUAD patients. Further results from in vivo and in vitro experiments confirmed that PLPP2 could induce excessive cell proliferation by enhancing lipid raft formation in LUAD cells.

conclusionsOur study has revealed the characteristics of gene expression profiles in early-stage LUAD patients with the different radiological and pathological subtypes, as well as deciphered transcriptomic evolution trajectory from preneoplasia to invasive LUAD. Furthermore, it suggests that PLPP2-mediated lipid raft synthesis may be a significant biological event in the initiation of early-stage LUAD, offering a potential target for more precise diagnosis and therapy in clinical settings.

Indexed as

Adenocarcinoma of LungLung NeoplasmsAnimalsCell ProliferationHumansMiceNerve Tissue ProteinsPhosphoric Monoester HydrolasesPrognosisRetrospective StudiesTranscriptomeNerve Tissue ProteinsPhosphoric Monoester HydrolasesPLPPR2 protein, humanCell proliferationEarly stage lung adenocarcinomaLipid raftsPhospholipid phosphatase 2Transcriptome sequencing

Identifiers

PMID37996944
PMCPMC10666437
OpenAlexW4388929317

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.